Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nicostatin: Phase III

Preliminary 1-year data from an ongoing open-label 800-patient Phase III study showed that Nicostatin reduced LDL and

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE